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Abstract
Background: We recently reported that colon tumor cells stimulate macrophages to release IL-1b, which in turn inactivates
GSK3b and enhances Wnt signaling in colon cancer cells, generating a self-amplifying loop that promotes the growth of
tumor cells.
Principal Findings: Here we describe that macrophages protect HCT116 and Hke-3 colon cancer cells from TRAIL-induced
apoptosis. Inactivation of IL-1b by neutralizing IL-1b antibody, or silencing of IL-1b in macrophages inhibited their ability to
counter TRAIL-induced apoptosis. Accordingly, IL-1b was sufficient to inhibit TRAIL-induced apoptosis. TRAIL-induced
collapse of the mitochondrial membrane potential (Dy) and activation of caspases were prevented by macrophages or by
recombinant IL-1b. Pharmacological inhibition of IL-1b release from macrophages by vitamin D3, a potent chemopreventive
agent for colorectal cancer, restored the ability of TRAIL to induce apoptosis of tumor cells cultured with macrophages.
Macrophages and IL-1b failed to inhibit TRAIL-induced apoptosis in HCT116 cells expressing dnIkB, dnAKT or dnTCF4,
confirming that they oppose TRAIL-induced cell death through induction of Wnt signaling in tumor cells. We showed that
macrophages and IL-1b stabilized Snail in tumor cells in an NF-kB/Wnt dependent manner and that Snail deficient tumor
cells were not protected from TRAIL-induced apoptosis by macrophages or by IL-1b, demonstrating a crucial role of Snail in
the resistance of tumor cells to TRAIL.
Significance: We have identified a positive feedback loop between tumor cells and macrophages that propagates the
growth and promotes the survival of colon cancer cells: tumor cells stimulate macrophages to secrete IL-1b, which in turn,
promotes Wnt signaling and stabilizes Snail in tumor cells, conferring resistance to TRAIL. Vitamin D3 halts this amplifying
loop by interfering with the release of IL-1b from macrophages. Accordingly, vitamin D3 sensitizes tumor cells to TRAIL-
induced apoptosis, suggesting that the therapeutic efficacy of TRAIL could be augmented by this readily available
chemopreventive agent.
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Introduction
Inflammation contributes to tumor progression by establishing
conditions that support tumor cell growth and survival and increase
their metastatic potential. Indeed, chronic inflammation has been
shown to predispose to development of a variety of tumors, a
striking example being inflammatory bowel disease, which is
associated with elevated risk of colon cancer [1]. Moreover, it
appears that colon cancers that do not develop as a complication of
inflammatory bowel disease are also driven by inflammation,
because it has been shown that regular use of NSAIDs lowers the
mortality from sporadic colon cancer and results in regression of
adenomas in FAP patients, who inherit a mutation in the Apc gene
[2]. Soluble factors which propagate inflammation can be produced
by tumor cells themselves or, more often, by cells recruited to the
tumor microenvironment, such as tumor associated macrophages
(TAMs). Coordinated signaling between tumor cells and nonma-
lignant cells in the tumor microenvironment is required for the
progression of tumors, and signaling pathways that regulate the
crosstalk between colon tumor cells and stroma, such as NF-kBa n d
STAT3, have emerged as important targets for chemopreventive
and chemotherapeutic agents [3,4]. Likewise, TNFa antagonists are
in phase I/II clinical trials and have been shown to be well tolerated
in patients with solid tumors [5,6].
We recently established that macrophages promote Wnt
signaling in colon cancer cells and thus enhance their proliferation,
and demonstrated that macrophages exert their protumorigenic
activity mainly through the release of IL-1b [7,8]. Here we show
that macrophage-derived factors, in addition to supporting the
growth of tumor cells, also promote their survival upon treatment
with TNF-related apoptosis inducing ligand (TRAIL), a potent
initiator of the extrinsic pathway of apoptosis.
TRAIL initiates apoptosis by binding to two death receptors,
DR4 and DR5, while binding to the decoy receptors which lack
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11700the death domain, such as DCR1, DCR2 and osteoprotegerin,
inhibits its pro-apoptotic activity [9]. Binding of TRAIL to the
death inducing receptors DR4/DR5 results in the recruitment of
the Fas –associated death domain (FADD) to the receptors, which
initiates binding of procaspase-8 and procaspase-9, and the
formation of the death inducing signaling complex (DISC) [9].
In type I cells, caspase-8 activation is sufficient to activate effector
caspases 3, 6 and 7, while in type II cells, the apoptotic cascade
requires integration of the mitochondrial pathway mediated by
caspase-8 induced cleavage of Bid.
Tumor cells are significantly more sensitive to TRAIL-induced
apoptosis than normal cells, establishing TRAIL and DR4 or DR5
agonistic antibodies as attractive anti-cancer drugs. Indeed, in stark
contrast to other members of the TNF family, treatment of mice and
primates with recombinant TRAIL induced significant regression of
tumors without systemic toxicity [10,11]. Recently, the combination
of TRAIL with all trans-retinyl acetate (RAc) has been shown to
induce apoptosis selectively in adenomatous polyposis (APC) deficient
epithelial cell without harming normal cellsaa and treatment of
Apc
Min mice with TRAIL and RAc induced apoptosis in intestinal
polyps and prolonged animal survival [12].
However, there are significant differences in TRAIL sensitivity
among human cancer cells. Resistance to TRAIL has been shown
to develop in cells with mutant DR5 [13] or in mismatch repair
deficient tumors with Bax mutations [14]. In contrast, c-Myc
promotes the responsiveness to TRAIL by inhibiting the
expression of FLIP, an inhibitor of TRAIL signaling [15], and
by counteracting TRAIL-induced upregulation of mcl-1 and
cIAP2, two proteins with intrinsic ability to inhibit apoptosis [16].
In addition, stromal cells and soluble factors present in the tumor
microenvironment have been shown to have a significant impact
on the sensitivity of tumor cells to therapeutic agents [17,18].
TRAIL deficient mice display increased susceptibility to
carcinogen induced tumorigenesis and have increased metastatic
potential [19,20], demonstrating that TRAIL exerts tumor
suppressor activity, and suggests an important role of endogenous
TRAIL in tumor surveillance. Indeed, the authors showed that
TRAIL is, at least in part, responsible for NK cell mediated, IFNc
dependent, mechanism of tumor elimination.
In this study we demonstrated that TRAIL induced apoptosis of
colon cancer cells is inhibited by macrophage derived IL-1b,a n d
showed that macrophages and recombinant IL-1b counteract
TRAIL-induced apoptosis through activation of Wnt signaling and
stabilizationofSnailintumorcells.Finally,wepresentdataindicating
that ‘‘normalization’’ of the tumor microenvironment by vitamin D3,
a potent chemopreventive agent, restores the sensitivity of colon
cancer cells to TRAIL, suggesting that the therapeutic efficiency of
TRAIL may be greatly improved by agents that inhibit the crosstalk
between tumor cells and the tumor microenvironment.
Materials and Methods
Cell lines and co-culture experiments
The HCT116 and Hke-3 colorectal carcinoma cell lines, which
differ only by the presence of the mutant k-Ras allele [21] and
SW480 cells were cultured in MEM, while 293T cells were
cultured in DMEM. The human monocytic cell line, THP1, was
cultured in RPMI. Normal human monocytes, .90% CD14 and
CD11c positive and less than 1% anti T cell receptor positive,
were purchased from Astarte Biologics (Redmond, WA). Tumor cells
and monocytes/macrophages were co-cultured separated by
transwell inserts of a polycarbonate membrane with 0.4 mM pore
size, which preclude direct cell-cell contact, but permit the
exchange of soluble factors (Corning Incorporated, Lowell, MA).
For clonogenic assay, HCT116 and Hke-3 cells were seeded at a
density of 200 cells per well of a six well plate alone or together with
THP1 macrophages or peripheral blood monocytes for 7 days.
Tumor cells were cultured with THP1 monocytes directly (1600 per
well of a 6 well plate), as THP1 cells did not attach and form colonies.
The optimal ratio between tumor cells and macrophages was
established previously [7,8]. Colonies were fixed and stained with 6%
glutaraldehyde and 0.5% crystal violet and counted using Total Lab
1.1 software (Nonlinear Dynamics, Durham, NC, USA).
Apoptosis assay
Cells were treated with recombinant TRAIL (50 ng/ml, which
we determined was the optimal concentration) alone or in the
presence of macrophages, IL-1b (5 ng/ml) or TNFa (10 ng/ml)
for 7 hours. Cells were resuspended in hypotonic buffer (0.1%
Triton X-100, 0.1% sodium citrate) and stained with propidium
iodide (50 mg/ml) for 4 hours at 4uC as described [22]. Samples
were analyzed by flow cytometry and cell cycle distribution and
the extent of apoptosis (cells with a subG1 DNA content) were
analyzed by the Modfit software. Mitochondrial membrane
potential was determined by flow cytometry using the fluorescent
dye JC-1 (Invitrogen). Cells were stained with 1 mM of JC1 for
1 hour at 37uC, washed with PBS and analyzed by fluorescence in
the FL2 channel. Cells were treated with TRAIL for ,7 hours
and were collected for evaluation based on morphological criteria.
However, as PI staining may underestimate the amount of
apoptosis [23], we confirmed the apoptotic nature of cells by
biochemical analysis of cell lysates. Statistical analysis was
performed using unpaired Student’s t test, with values ,0.05
considered statistically significant.
Transient transfection and Reporter gene assay
HCT116 and Hke-3 cells were transiently transfected with the
TOP-FLASH or TOP-FOP luciferase reporter plasmids using the
calcium phosphate method. Transfection efficiency was normal-
ized by co-transfection with pTK-Renilla and luciferase activity
was determined according to the vendor’s protocol (Dual
Luciferase reporter assay, Promega, Madison, WI). Dominant
negative IkBa was expressed from a plasmid coding for IkBa with
serines 32 and 36 mutated to alanine, which confers resistance to
stimulus induced degradation [24]. Plasmids expressing constitu-
tively active AKT, (HA-mdelta (4-129) PH-AKT), and dominant
negative AKT (HA-AKT-K179M) were provided by Richard
Roth [25,26]. dnTCF4 was described previously [27].
Macrophages were transfected with 20 nM of non specific siRNA
(NSP) or siRNAs specific for VDR, IL-1b or STAT1 (Dharmacon,
Lafayette, CO) using Lipofectamin LTX (Invitrogen, Carlsbad, CA).
The efficiency of silencing was monitored by immunoblotting (for
STAT1 and VDR), or by ELISA (for IL-1b), as reported [7,8].
Immunofluorescence
For the subcellular detection of b-catenin by immunofluores-
cence, cells were fixed in 4% paraformaldehyde for 30 minutes.
The cells were incubated with anti-b-catenin antibody (1:100) for
1 h at 37uC and with secondary anti-rabbit antibody conjugated to
FITC for 45 min at 37uC. Images were acquired with a SPOT
CCD camera and analyzed by SPOT software.
Western Blot
Western blots were performed using standard procedures.
Membranes were blocked with 5% milk in TBS containing
0.1% Tween 20, and incubated with antibodies specific for caspase
8 (Abcam), caspase 9, PARP, Snail (Cell Signaling Technology),
Interleukin 1b and TRAIL
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ences, San Jose, CA), and b-actin (Sigma Aldrich, St. Louis, MO).
Immunoreactive bands were visualized by chemiluminescence
(Amersham ECLTM western blotting detection kit, Piscataway,
NJ).
Results
Macrophages and IL-1b protect colon cancer cells from
TRAIL induced apoptosis
We demonstrated that macrophages induce several prosurvival
signaling pathways in colon cancer cells, including NF-kB, AKT
and Wnt signaling [7,8], suggesting that the presence of
macrophages could affect the response of tumor cells to
therapeutic agents. HCT116 colon cancer cells are highly
susceptible to TRAIL-induced apoptosis [16]. Accordingly,
TRAIL significantly inhibited the clonogenic growth of HCT116
and HKe-3 cells (Fig. 1A and B), cell lines that differ only by the
presence of the mutant kRas [21]. There was no reproducible
difference between the responsiveness of HCT116 and Hke-3 cells
to TRAIL (Fig. 1 and 2), demonstrating that the presence of
mutant kRas does not regulate the responsiveness of cells to
TRAIL. To determine whether macrophages alter the sensitivity
of tumor cells to TRAIL, we treated HCT116 and Hke-3 cells
with TRAIL in the absence or in the presence of THP1
macrophages. Remarkably, the presence of THP1 macrophages
or treatment with IL-1b, a cytokine produced in cocultures of
tumor cells and macrophages [7], restored the clonogenic growth
of TRAIL-treated colon cancer cells (Fig. 1).
Macrophages did not inhibit the expression of DR4 or DR5, or
modulate the levels of decoy receptors DcR1 or DcR2 in
HCT116/Hke-3 cells (Figure S1), suggesting that they do not
modulate the responsiveness to TRAIL through regulation of
TRAIL receptors.
Next we showed that macrophages and IL-1b inhibited TRAIL-
induced apoptosis of HCT116 and Hke-3 cells (Fig. 2A). THP1
macrophages and IL-1b precluded TRAIL-induced collapse of the
mitochondrial membrane potential (MMP) (Fig. 2B) and prevent-
ed TRAIL-induced activation of caspase-8 and caspase-9 (Fig. 2C).
The human monocytic cell line THP-1 was derived from the
Figure 1. Macrophages and IL-1b counteract TRAIL-induced inhibition of colon cancer growth. A and B: HCT116 and Hke-3 cells were
seeded at a density of 200 cells per well of a six well plate in the absence or the presence of macrophages (1600/well) or IL-1b, and were treated with
TRAIL for 4 hours. The results shown in B represent the average of two independent experiments each performed in duplicate.
doi:10.1371/journal.pone.0011700.g001
Interleukin 1b and TRAIL
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THP1 cells have properties of human monocyte-derived macro-
phages [28]. These cells have several characteristics of tumor
associated macrophages (TAMs), including impaired activation of
NF-kB, lack of nitric oxide production in response to LPS/IFNc
(not shown) and high constitutive STAT1 signaling [7,8].
However, to confirm that the results obtained using THP1 cells
are biologically relevant, we showed that normal peripheral blood
monocytes, precursors of the tumor associated macrophages,
protected a panel of colon cancer cell lines from TRAIL-induced
apoptosis (Fig. 2D). Like THP1 macrophages, normal peripheral
blood monocytes restored the MMP and prevented activation of
caspase 8 and cleavage of PARP in TRAIL-treated tumor cells
(data not shown, Figure S2), which is consistent with the ability of
colon cancer cells to induce IL-1b release from peripheral blood
monocytes [7].
Peripheral blood monocytes inhibited TRAIL-induced apopto-
sis also in 293T cells (Fig. 2D), demonstrating that macrophage-
derived factors are general and potent inhibitors of TRAIL-
induced cell death.
Macrophages protect from TRAIL-induced apoptosis
through IL-1b
We showed that IL-1b is sufficient to inhibit TRAIL-induced
apoptosis (Fig. 2). To establish whether IL-1b is required for
macrophage mediated protection of tumor cells from TRAIL-
induced apoptosis, we first silenced IL-1b in THP1 macrophages.
These experiments revealed that IL-1b deficient macrophages fail
to protect tumor cells from TRAIL-induced apoptosis (Fig. 3A and
3B). Consistent with these data, neutralization of IL-1b by IL-1b
specific antibody, or silencing of STAT1, a transcription factor
that we showed is required for the release of IL-1b from
macrophages [7] also inhibited the anti-apoptotic activity of
macrophages (Fig. 3A and 3B). As expected, neutralizing IL-1b
antibody inhibited the prosurvival activity of IL-1b, demonstrating
the specificity of antibody. Together, these data established that
tumor associated macrophages protect tumor cells from TRAIL-
induced apoptosis in an IL-1b dependent manner.
To determine whether the ability of IL-1b to interfere with therapy
induced apoptosis is restricted to TRAIL, we surveyed Oncomine
(www.oncomine.org), which is an assembly of human tumor
Figure 2. Macrophages and macrophage-derived factors protect colon cancer cells from TRAIL-induced apoptosis. A: HCT116
(average of 5 independent experiments) and Hke-3 cells (average of 4 independent experiments) were treated with TRAIL in the absence or the
presence of macrophages or IL-1b (5 ng/ml) as indicated and the extent of apoptosis was determined after 7 hours. B: The mitochondrial membrane
potential (MMP) was determined by JC1 staining 5 hours after treatment. C: Activation of caspase 8 and caspase-9 was determined in colon cancer
cells treated with TRAIL (50 ng/ml) under conditions indicated. D: TRAIL- sensitive cancer cell lines were treated with TRAIL in the absence or the
presence of human peripheral blood monocytes (Mo) and the extent of apoptosis was determined 7 hours after treatment. Data shown represent the
average of 2 or 3 independent experiments.
doi:10.1371/journal.pone.0011700.g002
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revealed that high expression of IL-1b in tumor cells lines strongly
correlates with the resistance of cells to vinblastine and doxorubicin
(Fig. 3C). The analysis of 70 metastatic colon tumors [30] revealed
that colon tumors that harbor mutant kRas have higher levels of IL-
1b than tumors with WT kRas (Fig. 3D, left panel). Whether IL-1b is
produced by stromal cells or tumor cells themselves cannot be
concluded, however the analysis of this database revealed that higher
levels of IL-1b in tumors correlate with resistance to cetuximab [30]
(Fig. 3D, right panel). In summary, these data established that the
levels of IL-1b are elevated in a subset of human colon tumors, and
that IL-1b modulates the response of tumor cells to a variety of
therapeutic agents both in vitro and in vivo.
Pharmacological inhibition of IL-1b stimulation by
Vitamin D3 inhibits the prosurvival activity of
macrophages
We recently demonstrated that the cross talk between tumor
cells and macrophages is disrupted by vitamin D3, an important
chemopreventive agent for colorectal cancer. Vitamin D3
inhibited the ability of tumor cells to stimulate IL-1b release from
macrophages [7] and, subsequently, vitamin D3 treated macro-
phages failed to induce Wnt signaling in tumor cells [7]. These
data suggested that vitamin D3 may also regulate TRAIL induced
apoptosis. HCT116 cells were cultured alone or in the presence of
macrophages, and were treated with TRAIL in the absence or the
presence of vitamin D3. Vitamin D3 did not affect TRAIL-induced
apoptosis in HCT116 or Hke-3 cells (data not shown), which is
consistent with the unresponsiveness of these cells to vitamin D3
[31]. However, we demonstrated that the ability of macrophages
to protect colon cancer cells from TRAIL-induced apoptosis was
inhibited by vitamin D3 (Fig. 4A). The addition of exogenous IL-
1b prevented the ability of vitamin D3 to regulate TRAIL induced
apoptosis, confirming that vitamin D3 restored the sensitivity of
tumor cells to TRAIL by inhibiting the release of IL-1b from
macrophages, and not by affecting signaling by IL-1b. Silencing of
VDR by VDR specific siRNA in macrophages did not affect their
ability to inhibit TRAIL-induced apoptosis in tumor cells, however
vitamin D3 failed to restore TRAIL induced apoptosis of tumor
Figure 3. IL-1b is sufficient and required to protect cells from TRAIL-induced apoptosis. A and B: HCT116 cells were cultured with THP1
macrophages with silenced IL-1b or STAT1 expression and were treated with TRAIL as indicated. IL-1b was neutralized by anti-IL-1b specific antibody.
Pictures were taken (A) and the amount of apoptosis (B) was determined after 7 hours. Data shown in B represent the average of three independent
experiments. C and D: Studies by Gyorffy et al ([29], C) and by Khambata-Ford et al ([30], D) were surveyed through Oncomine and indicate that cell
lines (C) and primary colon cancers (D) with higher levels of IL-1bdisplay resistance to therapeutic agents, such as vinblastine, doxorubicin and
cetuximab (CTX).
doi:10.1371/journal.pone.0011700.g003
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data demonstrated that vitamin D3 affects the crosstalk between
tumor cells and macrophages by targeting macrophages and not
the tumor cells, and that, accordingly, it requires the expression of
VDR on macrophages, consistent with our published data [7].
Biochemical analysis confirmed that while macrophages
inhibited TRAIL-induced activation of caspase 8 and caspase-9
and cleavage of PARP and b-catenin, treatment with vitamin D3
promoted TRAIL-mediated activation of the apoptotic cascade in
tumor cells that were grown in the presence of WT, but not VDR
deficient macrophages (Fig. 4B). As vitamin D3 acts as an inhibitor
of IL1-b release, its activity was prevented by exogenous IL1b and
was dependent on the expression of VDR on macrophages
(Fig. 4A, Fig. 4B) and not on tumor cells (data not shown).
Vitamin D3 also restored sensitivity to TRAIL in colon cancer
cells that were cultured in the presence of peripheral blood
monocytes. It enhanced activation of caspase 8 and subsequent
cleavage of PARP and b-catenin in HCT116 that acquired
resistance to TRAIL due to the presence of peripheral blood
monocytes (Figure S2).
These data suggest that the therapeutic efficacy of TRAIL could
be greatly improved by vitamin D3 in cancers that are infiltrated
by macrophages.
Wnt signaling is required for the prosurvival activity of
macrophages
We recently demonstrated that macrophages and IL-1b induce
Wnt signaling in colon cancer cells through activation of NF-kB-
dependent AKT signaling [8], pathways that have been shown to
protect tumor cells from apoptosis. To determine whether
macrophages and IL-1b inhibit TRAIL-induced apoptosis
through activation of these pro-survival signaling pathways, we
expressed in HCT116 cells dnIkB (an inhibitor of NF-kB
signaling), dnAKT (an inhibitor of AKT signaling) and dnTCF4
(an inhibitor of Wnt signaling). Inhibition of NF-kB or AKT did
not impact TRAIL-induced apoptosis. However, cells transfected
with dnTCF4 reproducibly showed a modestly reduced amount of
TRAIL-induced apoptosis (differences were not statistical signif-
icant), which may be consistent with the requirement of the Wnt
pathway for optimal TRAIL-induced apoptosis [32] (Fig. 5A).
However, the critical point was that in contrast to cells transfected
with an empty plasmid, macrophages and IL-1b did not protect
cells with impaired NF-kB, AKT or Wnt signaling from TRAIL-
induced apoptosis (Fig. 5A). We confirmed that macrophages and
IL-1b failed to counteract TRAIL-induced activation of caspase-8
and caspase-9 and subsequent cleavage of PARP in cells that
express either dnIkB, dnAKT or dnTCF4 (Fig. 5B). Of particular
interest, macrophages and IL-1b prevented TRAIL-induced
cleavage of b-catenin, but only in cells with intact NF-kB/
AKT/Wnt signaling (Fig. 5B).
Cleavage of b-catenin was mediated by caspases, as we could
prevent its processing by ZVAD, a pan-caspase inhibitor (Figure
S3). Cleaved b-catenin has been shown to exhibit impaired
transcriptional activity [33]. We showed that TRAIL inhibits
TCF4/b-catenin transcriptional activity and that macrophages
and IL-1b could partially restore b-catenin transcriptional activity
in TRAIL-treated cells (Figure S3).
Similar to published reports [34] we found that, despite the fact
that HCT116 cells carry a mutant b-catenin allele, most of b-
Figure 4. Pharmacological inhibition of IL-1b secretion by Vitamin D3 inhibits the prosurvival function of macrophages. A: The
amount of apoptosis was determined in HCT116 cells treated with TRAIL under indicated conditions. Error bars were derived from 2 independent
experiments. B: The effect of vitamin D3 on TRAIL-induced activation of caspases and the cleavage of PARP and b-catenin was determined by
immunoblotting.
doi:10.1371/journal.pone.0011700.g004
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with the cleavage of b-catenin by TRAIL, membranous
localization of b-catenin was severely diminished in TRAIL
treated cells (Fig. 5C). Both IL-1b and TNFa restored the
membranous localization of b-catenin in HCT116 cells in TRAIL-
treated cells (Fig. 5C), in accordance with their prosurvival activity.
Together, these data demonstrated that tumor associated
macrophages (TAMs) protect tumor cells from TRAIL-induced
apoptosis through their ability to stabilize b-catenin and to
promote Wnt signaling in colon cancer cells.
Macrophages, TNFa and IL-1b stabilize Snail in an NF-kB
and AKT/WNT dependent manner
Although macrophages and IL-1b protected tumor cells from
TRAIL-induced apoptosis, they did not regulate the levels of the
bcl-2 family members in tumor cells, such as Bcl-x or Mcl1, or
alter the expression of cIAPs, which have been shown to modulate
the response of cells to TRAIL-induced apoptosis [16] (data not
shown). However, we showed that the levels of Snail protein were
increased in HCT116 cells treated with IL-1b or in HCT116 cells
cultured in the presence of macrophages (Fig. 6A). TNFa, another
macrophage-derived factor that can induce Wnt signaling in
tumor cells [7,35], also elevated the levels of Snail in tumor cells
(Fig. 6A). We demonstrated that macrophages, IL-1b and TNFa
elevated Snail through NF-kB, AKT and Wnt signaling, as they
failed to increase the levels of Snail in cells expressing dnIkB,
dnAKT or dnTCF4 (Fig. 6A). The levels of Snail mRNA in
HCT116 or Hke-3 cells were not increased by macrophages (not
shown), suggesting that macrophage-derived factors stabilize Snail
protein in tumor cells. The induction of c-jun by IL-1b and TNFa
also required NF-kB, consistent with published data (Fig. 6A). We
showed that TNFa and IL-1b also failed to induce c-jun in cells
expressing dnTCF4, confirming the importance of Wnt signaling
for the biological activity of these cytokines and for the interaction
of tumor cells with macrophages.
GSK3b is a major kinase that phosphorylates Snail and induces
its degradation [36,37]. Because we reported that macrophages
and IL-1b inactivate GSK3b in tumor cells [7,8], we next
examined whether macrophages/IL-1b stabilize Snail through
inhibition of GSK3b. HCT116 and Hke-3 cells were treated with
LY294002, a PI3K inhibitor - and thus activator of GSK3b
(phoshorylation of GSK3b on Serine 9 inhibits its activity). As
shown in Fig. 6B, treatment of cells with LY294002 indeed
precluded macrophages/IL-1b/TNFa-mediated inactivation of
Figure 5. Wnt is required for the prosurvival activity of macrophages and IL-1b. A and B: HCT116 expressing dnIkB, dnAKT or dnTCF4 were
treated with TRAIL under indicated conditions and the amount of apoptosis was determined by propidium iodide staining. A: Data represent the
average of 5 independent experiments. B: The extent of caspase activation and the cleavage of PARP and b-catenin were determined in cell lysates by
immunoblotting. C: The localization of b-catenin was determined by immunofluorescence in HCT116 cells treated with TRAIL in the absence or the
presence of IL-1b or TNFa.
doi:10.1371/journal.pone.0011700.g005
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macrophages, TNFa and IL-1b. This result demonstrates that
inhibition of GSK3b regulates the stability of Snail in HCT116
cells and strongly suggests that macrophages, TNFa and IL-1b
stabilize Snail through their ability to inhibit GSK3b. Indeed,
pharmacological inhibition of GSK3b by LiCL or by GSK3b
specific inhibitor, AR-A014418, was sufficient to stabilize Snail in
tumor cells (Figure S4).
Finally, treatment of cells with LY29004 completely prevented
the ability of IL-1b to protect colon cancer cells from TRAIL-
Figure 6. Macrophages, IL-1b and TNFa stabilize Snail in a NF-kB/AKT/Wnt dependent manner. A: Macrophages, IL-1b and TNFa stabilize
Snail in a NF-kB/AKT/Wnt dependent manner. HCT116 cells were transfected with dnIkB, dnAKT or dnTCF4 and were treated with IL-1b or TNFa,o r
were cultured with THP1 macrophages as indicated. The levels of Snail and c-jun were determined by immunoblotting. B: The levels of Snail and
pGSK3b were determined by immunoblotting in Hke-3 cells that were treated with IL-1b, TNFa or were co-cultured with macrophages in the absence
or the presence of LY 294002 for 24 hours. C: HCT116 and Hke-3 cells were treated with TRAIL in the absence or the presence of IL-1b and LY294002,
as indicated. The experiment was performed three times.
doi:10.1371/journal.pone.0011700.g006
Interleukin 1b and TRAIL
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protect from TRAIL induced apoptosis through GSK3b depen-
dent stabilization of Snail.
Macrophages and IL-1b protect from TRAIL-induced
apoptosis through stabilization of Snail
Snail has been shown to interact with b-catenin and to promote
the expression of Wnt target genes [38]. In accord with these data,
we found that overexpression of Snail promotes TOP-FLASH-
driven activity in both HCT116 and Hke-3 cells (Fig. 7A). In order
to determine whether stabilization of Snail by macrophages/IL-1b
contributes to their ability to drive Wnt signaling, we silenced Snail
in tumor cells (Fig. 7B), and examined the ability of macrophages
and IL-1b to induce Wnt signaling in Snail deficient HCT116 and
Hke-3 cells. In contrast to HCT116 and Hke-3 cells transfected
with NSP(nontargeting) RNAi, cells transfected with Snail specific
RNAi failed to respond to macrophages and IL-1b with enhanced
Wnt signaling (Fig. 7C). Snail deficiency did not impair IL-1b
induced NF-kB activation in HCT116 cells (data not shown),
demonstrating a specific requirement for Snail in macrophage
mediated b-catenin driven transcription.
Finally, since we demonstrated that macrophages and IL-1b
protect from TRAIL-induced apoptosis through Wnt signaling
(Fig. 5), we tested whether macrophages can protect tumor cells
transfected with Snail siRNA from TRAIL-induced apoptosis.
Indeed, macrophages and IL-1b failed to inhibit TRAIL induced
apoptosis in Snail deficient HCT116 or Hke-3 cells (Fig. 8A),
confirming that macrophages and IL-1b protect from TRAIL-
induced apoptosis through stabilization of Snail in tumor cells.
Indeed, macrophages with silenced IL-1b or STAT1 (Fig. 8B) or
vitamin D3 treated macrophages (Fig. 8C), which failed to protect
tumor cells from TRAIL-induced apoptosis ([7], Fig. 4), also failed
to stabilize Snail in tumor cells.
These data established a pivotal role of Snail in inflammation-
induced resistance of tumor cells to TRAIL (Fig. 9).
Discussion
Acquired resistance to tumor therapy can develop as a result of
de novo genetic changes that accompany the progression of cancer.
In addition, tumors can attain resistance through a pathway that is
not intrinsic to tumor cells, but originates in the tumor
microenvironment, also called the tumor microenvironment
mediated drug resistance (TMMDR). Two types of TMMDR
have been described: resistance that is mediated by soluble factors
produced by the cells in the tumor microenvironment and
resistance that develops as a result of the adhesion of tumor cells
to stromal fibroblasts or to components of the extracellular matrix
[18]. It is therefore likely that therapeutic approaches that aim to
normalize the tumor microenvironment and/or interrupt the
crosstalk between the tumor cells and the microenvironment, will
Figure 7. Snail regulates Wnt signaling. A: HCT116 and Hke-3 cells were transfected with TOP-FLASH reporter together with an empty vector
(neo), or the increasing concentrations of Snail expression vector. The experiment was performed in triplicate. B: Tumor cells were transfected with
NSP or Snail specific siRNA and were treated with IL-1b as indicated. The levels of Snail were determined by immunoblotting. C: Tumor cells were
transfected with TOP-FLASH reporter together with NSP or Snail specific siRNA. Data represent the average of two independent experiments each
performed in duplicate.
doi:10.1371/journal.pone.0011700.g007
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potential to promote sensitivity of tumors to chemotherapy or
radiotherapy.
Recently we reported that vitamin D3, a potent chemopreven-
tive agent for colorectal cancer, inhibits growth of colon cancer
cells by targeting the tumor associated macrophages [7]. We
showed that vitamin D3 inhibited the ability of tumor cells to
induce the release of IL-1b from macrophages, and thereby
inhibited the subsequent increase in Wnt signaling and growth of
colon cancer cells. Here we present data which establish that
TRAIL responsive colon cancer cells acquire resistance to TRAIL
when cultured in the presence of macrophages, and showed that
macrophage-derived IL-1b was required for their anti-apoptotic
activity. Consistent with the ability of vitamin D3 to inhibit the
release of IL-1b from macrophages, vitamin D3 restored the
sensitivity of tumor cells to TRAIL. Macrophages were not general
inhibitors of apoptosis, as we demonstrated that they actually
promoted apoptosis of colon cancer cells in response to 5FU and
butyrate (Kaler et al, unpublished). Our preliminary results suggest
that macrophages promoted 5FU-induced apoptosis in an IL-1b
dependent manner, while the enhancement of butyrate induced
apoptosis was mediated though an unknown macrophage-derived
factor (Kaler et al, unpublished). This underscores the complexity
of the interactions between tumor cells and the stroma, and
emphasizes the specificity of the interactions between tumor cells
and environmentally derived factors, which is likely to contribute
to contrasting reports regarding prognostic significance of
macrophages in colon cancer [39]. The levels of IL-1b are
increased in colon cancer patients harboring mutant kRas and
elevated levels of IL-1b correlate with the resistance to cetuximab
(Fig. 3D) [30].
Cytokines secreted by the activated tumor stroma modulate tumor
growth and regulate their survival and invasiveness through
activation of oncogenic signaling pathways in tumor cells, examples
being activation of NF-kBb yT N F a and IL-1b, and activation of
STAT3 by IL-6 [4,40]. More recently, TNFa [35], Hepatocyte
Growth Factor [41], PDGF [42] and FGF19 [43] and IL-1b [7] have
been shown to activate Wnt/b-catenin signaling, the oncogenic
pathway activated in the majority of colorectal cancers.
Here we present data which demonstrate that macrophages and
IL-1b protect tumor cells from TRAIL-induced apoptosis through
induction of Wnt signaling in tumor cells, as cells expressing
dnTCF4 were not protected from TRAIL-induced apoptosis by
macrophages. Likewise, Wnt expressing rat embryonic fibroblasts
have been shown to inhibit TRAIL-induced apoptosis of human
leukemia cells [44].
Figure 8. Snail mediates the anti-apoptotic activity of macrophages and IL-1b. A: HCT116 and Hke-3 cells were transfected with NSP or
Snail specific siRNA and were treated with TRAIL in the absence or the presence of macrophages or IL-1b as indicated. Data represent the average of
two independent experiments. B and C: Silencing of IL-1b or STAT1 (B) in macrophages, or treatment with vitamin D3 (C) abrogates the ability of
macrophages to stabilize Snail in colon cancer cells.
doi:10.1371/journal.pone.0011700.g008
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induce Wnt signaling in an NF-kB dependent manner [8], we
showed that macrophages and IL-1b failed to inhibit TRAIL-
induced apoptosis in tumor cells expressing dnIkB, confirming the
oncogenic role of NF-kB signaling. It has been shown that the
ability of LPS, an inducer of IL-1b, to promote the growth of
CT26 tumors strictly depends on functional NF-kB signaling, and
that inhibition of NF-kB converts inflammation-induced tumor
growth to TRAIL-mediated tumor regression [45]. Our data
suggest that tumor cells with impaired NF-kB/Wnt signaling fail
to respond to survival signals from the tumor microenvironment
and thus undergo TRAIL-mediated cell death.
Myc has been shown to sensitize colon cancer cells to TRAIL
induced apoptosis through repression of MCL1 and cIAP2 in bax
deficient HCT116 cells [16]. In contrast, we have not observed
modulation of c-myc, MCL-1 or cIAP1 or cIAP2 in our system,
using HCT116 cells which are bax proficient. However, we
demonstrated that macrophages, TNFa and IL-1b increased the
levels of Snail in tumor cells, a known Wnt target gene and
regulator of tumor cell apoptosis [46]. Snail is a zinc finger
transcription factor that, through transcriptional repression of E
cadherin, induces an epithelial mesenchymal transition (EMT)
[47,48]. Although IL-1b was shown to upregulate Snail and to
downregulate E-cadherin in head and neck squamous carcinoma
cells [49], our initial analysis revealed no major changes in the
expression of epithelial or mesenchymal markers in colon cancer
cells exposed to macrophage-derived factors. The only mesenchy-
mal marker strongly induced in these cultures was fibronectin
(Kaler, not shown). However, more extensive analyses are
required to establish whether stabilization of Snail is sufficient to
promote an EMT in colon cancer cells.
GSK3b phosphorylates both the NES (nuclear export sequence)
and the destruction box in Snail and thereby triggers ubiquitin
mediated proteasomal degradation of Snail [37]. In addition,
inhibition of GSK3b has been also shown to activate the
transcription of Snail [36]. We showed that pharmacological
inhibition of GSK3b (Figure S4) or IL-1b mediated inhibition of
GSK3b (Fig. 6), were sufficient to elevate the levels of Snail in
colon cancer cells. This is in contrast to the recent report that
TNFa stabilized Snail through NF-kB-dependent induction of
CSN2 in breast cancer cells, which inhibited the association of
Snail with GSK3b and thus suppressed its phosphorylation and
degradation [50].
Wnt signaling has been shown to promote transcription, protein
stability and to regulate nuclear localization of Snail [36,37]. In
turn, Snail interacts with b-catenin and increases the expression of
Wnt target genes [38]. Likewise, Gli1, the hedgehog pathway
transcription factor, has been shown to promote Wnt signaling
through induction of Snail [51]. We showed that macrophage-
induced stabilization of Snail contributes to Wnt signaling in colon
cancer cells and creates a positive feedback loop initiated, and
propagated, by macrophage-derived IL-1b. In the Apc
Min mouse
model of intestinal tumorigenesis, inhibition of Snail increased cell
death and reduced tumor formation [52] and in human tumors,
nuclear b-catenin activity is enhanced at the invasive front, where
the expression of E-cadherin, a direct target of Snail, is
downregulated [53], suggesting that this positive regulatory
signaling is functional in vivo.
Figure 9. Crosstalk between tumor cells and macrophages which propagates the growth and survival of cancer cells. Tumor cells
activate macrophages to secrete IL-1b which in a NF-kB/AKT dependent manner inactivates GSK3b and thus promotes Wnt signaling in tumor cells.
Elevated levels of c-myc contribute to enhanced growth of tumor cells, while increased levels of Snail contribute to enhanced Wnt signaling, protect
cells from TRAIL induced apoptosis, and are likely to contribute to the epithelial mesenchymal transition (EMT) and enhanced metastatic potential of
tumor cells.
doi:10.1371/journal.pone.0011700.g009
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breast cancer cells by inducing epithelial mesenchymal transition
(EMT) via NF-kB dependent stabilization of Snail [50]. Our data
suggest that colon cancer cells with stabilized Snail escape TRAIL-
induced cell death, a novel mechanism whereby Snail promotes
tumor progression.
Many studies have investigated the role of genetic and
epigenetic changes in the responsiveness of tumor cells to TRAIL.
This report establishes that the proinflammatory tumor microen-
vironment can render tumor cells resistant to TRAIL. Consistent
with our data, TRAIL induced apoptosis is inhibited by IL8 in
ovarian cancer cells [54,55], by IL-1b in keratinocytes [56,57],
and by IL6 in multiple myeloma cells [58]. Neutralization of IL4
significantly enhanced the effectiveness of TRAIL in epithelial
tumors [59], confirming that factors derived from the tumor
microenvironment can diminish the response of tumor cells to
TRAIL. We established that vitamin D3, which interrupts the
crosstalk between tumor cells and macrophages, restores the
sensitivity of colon cancer cells to TRAIL. Because TRAIL is a
promising therapeutic agent, these data offer an exciting
opportunity to pharmacologically enhance the responsiveness of
cancer patients to TRAIL by commonly used chemopreventive
agent. Our data suggest that such an approach should be
beneficial in patients with tumors that have a high level of
infiltration of macrophages and therefore may not respond to
TRAIL alone.
Supporting Information
Figure S1 The expression of TRAIL receptors on tumor cells:
The expression of DR4, DR5, DcR1 and DcR2 mRNA in
HCT116 and Hke-3 cells that were cultured alone or together
with THP1 macrophages, and were either left untreated or were
treated with vitamin D3.
Found at: doi:10.1371/journal.pone.0011700.s001 (0.19 MB TIF)
Figure S2 Vitamin D inhibits the anti-apoptotic activity of
peripheral blood monocytes (Mo). HCT116 and Hke-3 cells were
treated with TRAIL in the absence or the presence of peripheral
blood monocytes and vitamin D, as indicated. The extent of
apoptosis was determined by PI staining (left panel), and the
activation of caspase 8 and cleavage of PARP and beta catenin
were determined by immunoblotting (right panel).
Found at: doi:10.1371/journal.pone.0011700.s002 (0.12 MB TIF)
Figure S3 TRAIL inhibits beta-catenin/TCF4 transcriptional
activity. A: HCT116 and Hke-3 cells were treated with TRAIL in
the presence of pan-caspase inhibitor, ZVAD, and the cleavage of
PARP and beta-catenin was determined by immunoblotting. B:
HCT116 and Hke-3 cells were transfected with the TOP-FLASH
reporter gene and were treated with TRAIL (10 ng/ml) in the
presence of macrophages or IL1 as indicated for 24 hours.
Found at: doi:10.1371/journal.pone.0011700.s003 (0.16 MB TIF)
Figure S4 Inhibition of GSK3beta stabilizes Snail in tumor cells.
HCT116 cells were treated with LiCl (10 mM) or with AR-
A014418 (AR, 50 mM) for 24 hours and the levels of Snail and
beta actin were determined by immunoblotting.
Found at: doi:10.1371/journal.pone.0011700.s004 (2.24 MB TIF)
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